[Featured Stock] Samsung Biologics Hits 2 Trillion Won Order Jackpot, Rises Over 2%

Samsung Biologics, which signed a contract worth 2 trillion won, is showing strong performance in the early trading session on the 14th.

원본보기 아이콘

According to the Korea Exchange, as of 9:18 a.m. on the same day, Samsung Biologics is trading at 1,035,000 won, up 2.27% (23,000 won) from the previous trading day.

Samsung Biologics announced that it signed a mega contract for contract manufacturing organization (CMO) worth $1.41011 billion (approximately 2.0747 trillion won) with a European pharmaceutical company. This contract is the largest in Samsung Biologics' history since its establishment and accounts for about 40% of last year's total order amount (5.4035 trillion won). The contract period is until December 31, 2030, and the client and product names are not disclosed due to confidentiality agreements.

On the 8th, Meritz Securities maintained a 'Buy' investment rating and a target price of 1.3 million won for Samsung Biologics, citing continued expectations for the passage of the U.S. Biosecurity Law.

Junyoung Kim, a researcher at Meritz Securities, said, "Last year, the failure to pass the Biosecurity Law raised doubts about its implementation, but expectations have been renewed as Wuxi Biologics in China sold its vaccine production facility in Ireland to Merck," adding, "Wuxi AppTec also showed preparations for the passage of the Biosecurity Law by selling its cell and gene therapy business unit to a U.S. private equity fund."

The Biosecurity Law, proposed last year, includes provisions restricting transactions between U.S. federal agencies and companies and Chinese biotech companies.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.